Summary
Data from a French placebo-controlled double-blind trial in 120 female patients treated with high dose fluorouracil, epirubicin and cyclophosphamide (HD-FEC) chemotherapy for inflammatory breast cancer were used to assess the economic impact of adjunctive lenograstim therapy. The analysis compared direct costs of treatment, with or without lenograstim, with reference to the Social Security (Germany) or to the National Health Service (Italy).
Resource utilisation differed between the 2 treatment groups. The lenograstim group reported 32% fewer antibiotic therapy days (9.8 days vs 14.6; p = 0.01) and 24% fewer inpatient days for any reason other than chemotherapy (7.4 ‘excess’ days vs 9.8). By reducing infection-related morbidity associated with a high dose chemotherapy regimen, lenograstim decreased treatment costs by DM 1794 and ItL 1.2 million, excluding the cost of lenograstim itself.
Since lenograstim patients reported fewer chemotherapy delays (16.4 vs 30.5%) and, hence, benefited from 1.2 (p = 0.04) more chemotherapy days, the related cost was DM 1519 and ItL 0.9 million higher than for the placebo group. This cost difference would be expected to be smaller if the placebo group patients had been followed until completion of their full chemotherapy regimen.
Assuming that the costs of chemotherapy were the same for both groups, the direct cost saving for the lenograstim group would be 30% in Germany and 34% in Italy.
Similar content being viewed by others
References
Chevallier B, Chollet P, Merrouche Y, et al. Glycosylated rHuG-CSF (lenograstim) prevents morbidity from FEC-HD chemotherapy in inflammatory breast cancer (IBC). Proc Am Soc Clin Oncol 1993; 12(3) 84AB: 137
Gisselbrect C, Lapage E, Haioun C, et al. Lenograstim (glycosylated recombinant human G-CSF) supported chemotherapy optimization in aggressive non Hodgkin’s lymphoma (NHL). Proc Am Soc Clin Oncol 1993; 12(3): 363 AB: 1226
Fossat C, Stoppa AM, Sainty D, et al. In vivo stimulation of neutrophil function by lenograstim (glycosylated rHuG-CSF) in oncohematologic patients: results of a phase I trial. Stem Cells 1994; 12: 322–8
Andersen HH, Henke K-D, Schulenburg JM. Basiswissen Gesundheitsökomie. Berlin: Sigma, 1992
Backhouse ME, Backhouse RJ, Edey SA. Economic evaluation bibliography. Health Economics 1992; Suppl.: 1–236
Drummond M, Menzin J, Oster G. Methodological issues in economic assessments of new therapies: the case of colony-stimulating factors. PharmacoEconomics 1994; 6 Suppl. 2: 18–26
Moore MP, Ihde JK, Crowe Jr JP, et al. Inflammatory breast cancer. Arch Surg 1991; 126: 304–6
Ackland SP, Bitran JD, Dowlatshahi K. Management of locally advanced and inflammatory carcinoma of the breast. Surg Gynecol Obstet 1985; 161: 399–408
Der Bundesminister für Gesundheit. Daten des Gesundheitswesens. Baden-Baden: Nomos-Verlag, 1991
Bundesverband der Pharmazeutischen Industrie e.V. Rote Liste 1993. Aulendorf: Editor Cantor, 1993
CTSP-Ministero del Tesoro. La variabilità dei costi di erogazione dei servizi ospedalieri tra le regioni. Roma: 1993
SCPS-Ministero della Sanità. Rendiconti delle unità sanitarie locali. Roma: 1991
Ministero della Sanità. Determinazione del prezzo unitario di cessione della unità di sangue tra servizi sanitari. DM 18.9.1991
Lucioni C, Rossi F. L’economia della plasmaferesi. Milano: Angeli, 1986
Schulenburg JM, Schoeffski O. Ökonomische Evaluation onkologischer Therapie. Munch Med Wochenschr 1994; 136: 217–20
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mapelli, V., Graf v.d. Schulenburg, J.M., Laaser, U. et al. Economic Evaluation of Lenograstim (Glycosylated rHuG-CSF) in the Treatment of Inflammatory Breast Cancer for Germany and Italy. Pharmacoeconomics 6 (Suppl 2), 27–35 (1994). https://doi.org/10.2165/00019053-199400062-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199400062-00006